Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile

作者：Myriam El Gaaloul, André-Marie Tchouatieu, Kassoum Kayentao, Brice Campo, Bénédicte Buffet, Hanu Ramachandruni, Jean Louis Ndiaye, Timothy N. C. Wells, Céline Audibert, Jane Achan, Cristina Donini, Hellen C. Barsosio, Halidou Tinto · 发表于：Malaria Journal · 年份：2024 · DOI：10.1186/s12936-024-05128-1 · 被引用次数：16 · 研究领域：Malaria Research and Control、Computational Drug Discovery Methods、Mosquito-borne diseases and control

Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector control and chemopreventive medicines with over 50 million children receiving seasonal malaria chemoprevention in the year 2023. Two vaccines are approved and starting to be deployed, bringing additional protection for children up to 36 months. However, the impact of these currently available tools is somewhat limited on various fronts. Vaccines exhibit partial efficacy, are relatively costly, and not accessible in all settings. The challenges encountered with chemoprevention are barriers to acceptability and feasibility, including frequency of dosing, and the lack of options in the first trimester of pregnancy and for women living with HIV. Also, the emergence of resistance against chemopreventive medicines is concerning. To address these limitations, a target product profile (TPP) is proposed as a road map to guide innovation and to boost the quest for novel chemopreventive alternatives. This TPP describes the ideal product attributes, while acknowledging potential trade-offs that may be needed. Critically, it considers the target populations most at risk; primarily infants, children, and pregnant women. Malaria control and elimination requires appropriate chemoprevention, not only in areas of high endemicity and transmission, but also in lower transmission areas where immun...